Instead of just JAKi, why don't we look at all our RA meds and MACE risk FAERS data & reporting odds ratios here: all the caveats of voluntary reporting, so don't put too much weight, but... prednisone. Don't forget pred is really not great for MACE! #ACR24 ABST1981 @RheumNow https://t.co/L9SlPZF2Jd

• https://x.com/drdavidliew/status/1858471335137276261/photo/1

Always looking for cancer/CV signals from JAKi in big observational datasets w extensive JAKi use nationwide 🇯🇵 claims data RA pts n=52k (JAKi n=4.3k) Cancer with JAKi vs TNFi: aHR 2.2 (esp lung, lymphoma) This is a problem. Watch these data. #ACR24 ABST1336 @RheumNow #ACRBest https://t.co/vsnT46De6T

• https://x.com/drdavidliew/status/1858460642396574028/photo/1

ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey

• Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in …
• https://x.com/drdavidliew/status/1858459066185740599/photo/1

Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow https://t.co/w58MNqRt1T

• https://x.com/drdavidliew/status/1858475993591157006/photo/1

Upadacitinib in Behcet's disease - would be very much welcomed, and this open label 8 patient pilot from China is encouraging. We saw similar data for tofacitinib before @ARD_BMJ: https://t.co/YlAQVXpnTY JAKi (?generic) could be a fantastic option! #ACR24 ABST2515 @RheumNow https://t.co/65friNLUOK

• A pilot study of tofacitinib for refractory Behçet’s syndrome
• https://x.com/drdavidliew/status/1858481726164783377/photo/1

Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution. Persistent higher doses earlier on might dampen ICI response. @HSpecialSurgery ICI-IA (inflamm arthritis) cohort big diff in survival based on early steroid exposure #ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw

• https://x.com/drdavidliew/status/1858483970268401794/photo/1

Rheumatic irAEs can get on the CAR-T bandwagon, too! CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience. Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to... #ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr

• https://x.com/drdavidliew/status/1858485108338291164/photo/1

Now that nipocalimab is approved for Sjogren's Disease, what about vaccination response whilst on this FcRn inhibitor (inherently lowers IgG)? Actually, not bad: takes a little longer to get there, but reassuring! (always fun to get to know a new med) #ACR24 ABST1988 @RheumNow https://t.co/IYqIGo5xVP

• https://x.com/drdavidliew/status/1858486947909636452/photo/1

Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies. All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about. #ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d

• https://x.com/drdavidliew/status/1858489054561816946/photo/1